Scarica l'app Stockscreener
5.16
2.63%
-0.16
Precedente Chiudi:
$5.32
Aprire:
$5.29
Volume 24 ore:
11,178
Relative Volume:
0.09
Capitalizzazione di mercato:
$44.06M
Reddito:
$140.46M
Utile/perdita netta:
$-146.34M
Rapporto P/E:
-4.063
EPS:
-1.27
Flusso di cassa netto:
$-117.73M
1 W Prestazione:
-15.77%
1M Prestazione:
+4.65%
6M Prestazione:
-55.33%
1 anno Prestazione:
-69.97%
Intervallo 1D:
$5.10
$5.30
Intervallo di 1 settimana:
$4.64
$5.9599
Portata 52W:
$3.51
$17.85
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Nome
Karyopharm Therapeutics Inc
Settore
Industria
Telefono
617-658-0600
Indirizzo
85 WELLS AVENUE, NEWTON, MA
Confronta KPTI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
5.10 | 53.14M | 140.46M | -146.34M | -117.73M | -1.27 |
|
ONC
Beigene Ltd Adr
|
231.35 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.06 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3045 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.77 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.68 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-01-19 | Iniziato | Piper Sandler | Overweight |
| 2022-11-04 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-11-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-08-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-08-06 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | Iniziato | Morgan Stanley | Overweight |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-17 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-07-23 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-07-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-05 | Reiterato | Robert W. Baird | Outperform |
| 2019-03-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-02-28 | Reiterato | BofA/Merrill | Underperform |
| 2019-02-27 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | Iniziato | B. Riley FBR | Buy |
| 2018-11-09 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2018-05-24 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-04-02 | Ripresa | Leerink Partners | Outperform |
| 2017-11-15 | Ripresa | H.C. Wainwright | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2016-09-08 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-30 | Aggiornamento | Jefferies | Hold → Buy |
| 2016-08-18 | Iniziato | H.C. Wainwright | Buy |
| 2016-06-28 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Karyopharm Therapeutics Inc Borsa (KPTI) Ultime notizie
Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference | KPTI Stock News - GuruFocus
Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference - PR Newswire
StockNews.com Downgrades Karyopharm Therapeutics (NASDAQ:KPTI) to Sell - Defense World
Leerink Partnrs Issues Positive Estimate for KPTI Earnings - Defense World
Brokerages Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target at $45.60 - Defense World
Karyopharm targets $1B peak U.S. revenue in myelofibrosis as Phase 3 SENTRY enrollment nears completion - MSN
Karyopharm’s Earnings Call: Clinical Gains Amid Financial Strains - TipRanks
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2025 Earnings Call Transcript - Insider Monkey
Robert W. Baird Issues Pessimistic Forecast for Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price - Defense World
Karyopharm Announces Poster Presentation on Selinexor in Myelofi - GuruFocus
KPTI to Present Promising Selinexor Data at Upcoming Hematology Meeting | KPTI Stock News - GuruFocus
Karyopharm abstract selected for presentation at 2025 EHA meeting - TipRanks
Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting - PR Newswire
KPTI: RBC Capital Lowers Price Target while Maintaining Outperfo - GuruFocus
RBC Capital cuts Karyopharm stock price target to $33 By Investing.com - Investing.com Canada
These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results - Benzinga
KPTI Misses Q1 Revenue Estimates but Advances Myelofibrosis Tria - GuruFocus
KPTI Stock Boosted as Barclays Raises Price Target to $10 | KPTI - GuruFocus
Karyopharm (KPTI) Target Price Reduced by RBC Capital | KPTI Sto - GuruFocus
KPTI: Baird Lowers Price Target but Maintains Outperform Rating - GuruFocus
Karyopharm (KPTI) Price Target Reduced by Baird, Outperform Rati - GuruFocus
Karyopharm Therapeutics Inc Reports Q1 2025 Earnings: EPS Loss o - GuruFocus
RBC Adjusts Price Target on Karyopharm Therapeutics to $33 From $43, Maintains Outperform Rating - marketscreener.com
Barclays Updates Karyopharm (KPTI) Price Target, Eyes Future Dat - GuruFocus
Karyopharm Therapeutics Inc (KPTI) Q1 2025 Earnings Call Highlights: Promising Clinical ... - Yahoo Finance
Karyopharm Therapeutics Inc (KPTI) Q1 2025 Earnings Call Highlig - GuruFocus
Karyopharm Q1 2025 slides: Myelofibrosis opportunity takes center stage By Investing.com - Investing.com Canada
Karyopharm Therapeutics Reports Q1 2025 Earnings and Clinical Progress - TipRanks
Earnings call transcript: Karyopharm Q1 2025 shows mixed market reaction By Investing.com - Investing.com Nigeria
Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modificati - Citizen Tribune
Earnings call transcript: Karyopharm Q1 2025 shows mixed market reaction - Investing.com
KPTI Projects Funding into Early 2026 Supported by XPOVIO Sales - GuruFocus
Karyopharm Reports First Quarter 2025 Financial Results and Anno - GuruFocus
Karyopharm Therapeutics: Q1 Earnings Snapshot - San Antonio Express-News
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Karyopharm Q1 2025 slides: Myelofibrosis opportunity takes center stage - Investing.com
Karyopharm Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Karyopharm Therapeutics Inc. SEC 10-Q Report - TradingView
Karyopharm Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025 - Longview News-Journal
Investor Network: Karyopharm Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025 | KPTI Stock News - GuruFocus
Redefining Myelofibrosis Care: Can Karyopharm's Selinexor Lead The Way? - RTTNews
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Citizen Tribune
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq L - GuruFocus
Karyopharm Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 200-Day Moving Average – Here’s Why - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Karyopharm Therapeutics Inc Azioni (KPTI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):